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INTRODUCTION
Nausea and vomiting are major concerns of patients
being treated with high-dose chemotherapy [1]. Sero t o n i n
( 5 - H T-3) antagonists have proven effective in providing con-
t rol of nausea and vomiting, likely due to their effects on the
interaction of serotonin produced by the entero c h ro m a ffin
cells with receptors in the vomiting center [2]. Comparative
studies have tested the most commonly used sero t o n i n
antagonists, granisetron and ondansetron, in the setting of
highly emetic chemotherapy regimens and have shown them
to have comparable effectiveness [2–8]. In addition, both
o n d a n s e t ron and granisetron have been shown to be eff e c t i v e
during bone marrow transplantation (BMT) [9–15]. Howev-
e r, no trials have tested these agents in a double-blinded, ran-
domized fashion to determine their relative efficacy in con-
t rolling emesis during the pre p a r a t o ry regimens associated
with BMT. In addition, relatively few data are available with-
in a single study re g a rding the response of children and
adults to anti-emetic therapy. 
This study was undertaken to determine the ability of
o n d a n s e t ron and granisetron to control emetic episodes
and nausea during the conditioning regimen of transplanta-
tion. In addition, we sought to identify groups that may be
at high risk for poorly controlled emesis and nausea.
Patients receiving any of the standard conditioning re g i-
mens at the University of Minnesota were eligible, and the
g roups were stratified to adult and pediatric populations.
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ABSTRACT
To determine the comparative anti-emetic efficacy of ondansetron and granisetron in patients undergoing bone
m a rrow transplantation, we perf o rmed a double-blind, randomized trial in pediatric and adult patients re c e i v i n g
transplants at the University of Minnesota. The results in 187 patients stratified by age (,18 years, n551; $1 8
years, n5136) were analyzed. The average number of emetic episodes in the entire group from day –7 to 2 was
0.86/day for patients receiving ondansetron and 0.73/day for those receiving granisetron (p 5 0.32). No diff e re n c e s
w e re noted between the two drugs in total days of complete or major control of emesis or in the number of re q u e s t s
for additional drugs to alleviate symptoms of nausea. The use of total-body irradiation–containing conditioning re g-
imens was associated with a decreased number of emetic episodes compared with regimens of chemotherapy alone.
P e rceived nausea was evaluated using a nausea scoring system, and no diff e rences were apparent between the
g r a n i s e t ron and ondansetron groups; however, re p o rted nausea was significantly higher in females (p , 0.01) and in
the adult population (p 5 0.05). We conclude that both ondansetron and granisetron provide good control of nausea
and vomiting experienced with conditioning regimens for bone marrow transplantation. The relative cost of the
d rugs within an institution must be considered in developing standard anti-emetic regimens for bone marro w
transplantation. 
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Data were collected regarding objective (episodes of emesis,
overall control of vomiting) and subjective (reported nausea
scores, requests for additional anti-emetic medications) cri-
teria related to drug effectiveness. All patients in the study
received either granisetron or ondansetron as well as dexam-
ethasone, as it has been shown that dexamethasone may
enhance the efficacy of serotonin antagonists [16,17]. 
PATIENTS AND METHODS
Pa t i e n t s
Eligible patients included individuals 2–65 years of age
not currently being treated with anti-emetic medications and
not having a history of recent emetic episodes pre c e d i n g
conditioning therapy; an exception was made for patients
with nausea or vomiting due to recent anesthesia. A total of
193 patients undergoing hematopoietic cell transplantation
w e re randomized; of those, four withdrew within 48 hours of
randomization and two had inadequate data for analysis.
Data on the remaining 187 patients are re p o rted. In addition
to the randomization between granisetron and ondansetro n ,
a stratification was perf o rmed based on age (2–17 and $1 8
years of age). Patient characteristics are provided in Table 1.
T h e re were no significant diff e rences between patients ran-
domized to receive ondansetron or granisetron based on age,
sex, diagnosis, conditioning regimen, or type of transplant
(autologous, allogeneic, unrelated). Age at transplantation
ranged from 2 to 62 years of age, with 51 patients (27%)
,18 years old. Of patients receiving transplants, 144 (77%)
received a pre p a r a t o ry regimen including total-body irr a d i a-
tion (TBI); the distribution was similar in the pediatric and
adult populations (78% and 76%, respectively). Ve ry few
adult patients (five of 136, 4%) were transplanted for nonma-
lignant conditions, including severe aplastic anemia (SAA)
and metabolic disorders. In contrast, the pro p o rtion of chil-
d ren transplanted for nonmalignant conditions was notably
higher (26 of 51, 51%), and included patients with SAA,
immune deficiencies, and metabolic disorders. While the
overall distribution of autologous, related, and unre l a t e d
donor transplants was similar (36%, 27%, and 36%, re s p e c-
tively), a higher pro p o rtion of pediatric patients re c e i v e d
u n related donor transplants (35 of 51, 68%) compared with
adult patients (33 of 136, 24%). In contrast, the pro p o rt i o n
of pediatric patients who received autologous marrow (eight
of 51, 16%) was lower than that of adults (60 of 136, 44%).
Eight pediatric patients received marrow from a re l a t e d
donor (16%); 43 adult patients (32%) had a related donor. 
Study design
The objective of these investigations was to compare the
relative efficacy of granisetron and ondansetron in control-
ling nausea and vomiting associated with BMT. The study
was designed as a double-blind, randomized trial in which
patients received either granisetron or ondansetron 30 min-
utes before the initiation of the ablative regimen; adminis-
tration continued through day 0. In the ondansetron arm ,
patients received an initial loading dose before the start of
the first dose of chemotherapy or TBI, followed by a con-
tinuous infusion. Infusions of ondansetron were adminis-
tered on the basis of previous experience at our institution,
ease of administration (a single infusion was prepared daily
as opposed to every 4- or 6-hour dosing), and pre v i o u s
reports of efficacy [9,10]. An 8-mg load was administered to
patients $18 years old followed by a 0.015 mg/kg/h drip
rounded to the nearest 0.5 mg/h, amounting to ~24 mg/day
for a 70-kg individual. Participants ,18 years old received a
0.15 mg/kg load along with a 0.03 mg/kg/h drip rounded to
the nearest 0.1 mg. A placebo consisting of an intermittent
dose of 5% dextrose was administered every 12 hours. In the
granisetron arm, a single intravenous dose of the drug was
given before the start of chemotherapy or TBI followed by
i n t e rmittent intravenous dosing of granisetron every 12
hours. Patients $18 years old received 7.5 µg/kg/dose (~0.5
mg for a 70-kg patient) every 12 hours; those ,18 years old
received 10 µg/kg/dose every 12 hours. Patients on this arm
received a placebo consisting of a continuous infusion of 5%
d e x t rose. All patients received dexamethasone,  10
mg/m2/day intravenously for patients ,18 years old (maxi-
mum 10 mg) and 10 mg/day intravenously for patients $18
years old. For “bre a k t h rough” nausea/vomiting, additional
medications were available on request. Patients $18 years
old received lorazepam 0.5 mg or prochlorperazine 10 mg
intravenously every 4–6 hours as needed. Patients ,18 years
old received lorazepam 0.05 mg/kg intravenously every 4–6
hours as requested or promethazine 0.25–1.0 mg/kg every
4–6 hours. Other anti-emetic support was considered as
needed. 
Table 1. Patient-related information
Granisetron Ondansetron p
Number in analysis 90 97
Age NS
,18 y 23 (26%) 28 (29%)
$18 y 67 (74%) 69 (71%)
Median (range) 41 (3–62) 36 (2–62)
Weight in kg (range) 73 (11–132) 71 (11–126)
Recipient sex NS
Female 36 (40%) 44 (45%)
Male 54 (60%) 53 (55%)
Type of transplant NS
Autologous 34 (38%) 34 (35%)
Allogeneic 24 (27%) 27 (28%)
Unrelated 32 (35%) 36 (37%)
Diagnosis NS
Nonmalignancy 16 (18%) 15 (15%)
Aplastic anemia 9 (10%) 4 (4%)
Immune deficiency 2 (2%) 1 (1%)
Metabolic disorder 5 (6%) 10 (10%)
Malignancy 74 (82%) 82 (85%)
Acute lymphocytic leukemia 1 (1%) 5 (5%)
AML/MDS 17 (19%) 24 (25%)
Chronic myeloid leukemia 26 (29%) 23 (24%)
Lymphoma 10 (11%) 10 (26%)
Breast cancer 7 (8%) 5 (26%)
Other malignancy 13 (14%) 15 (26%)
Conditioning regimen NS
Chemotherapy and radiation 66 (73%) 78 (80%)
Chemotherapy alone 24 (27%) 19 (20%)




To obtain objective information regarding the control of
emesis, the frequency of emetic episodes was evaluated from
the first day of the preparative regimen through day 2. An
emetic episode was defined as expulsion of stomach contents
separated by 1 minute from a previous episode; if repeated
vomiting occurred with ,1 minute of separation, it was
considered a single episode. Retching was defined as a non-
productive emptying of stomach contents. A series of retch-
es lasting ,5 minutes was considered one emetic episode.
The nursing staff recorded the number of emetic episodes as
well as requests for additional anti-emetic therapy. To obtain
information regarding the perception of nausea experienced
by the patient, a visual analog scale containing smiling or
frowning faces was used for both pediatric and adult patients
to determine the severity of nausea (a 5-point scale where
0 5 no nausea and 5 5 worst nausea ever experienced).
Visual analog scales have been used in studies with pediatric
oncology patients as young as 2 years of age [18,19].
Patients were asked to report their degree of nausea on this
scale daily at noon from the beginning of their ablative regi-
men through day 0. Control over emesis was determ i n e d
based on the following determinations: complete contro l
was defined as no emetic episodes and major control was
d e fined as one to two emetic episodes in 24 hours. Minor
c o n t rol constituted more than two (three to five) emetic
episodes in 24 hours, and more than five emetic episodes in
24 hours or the administration of more than two doses of
rescue drugs per day defined complete failure.
Statistical considerations
To compare the number of daily emetic episodes and
nausea scores over time between the randomized anti-emetic
treatments granisetron and ondansetron, we used a general
linear mixed model in a repeated-measures regression analy-
sis (SAS‚ PROC MIXED). To assess potentially import a n t
confounders, the following factors were also included in our
models: age, sex, diagnosis (malignancy vs. no malignancy),
conditioning regimen (TBI vs. no TBI), type of transplant
(autologous vs. related vs. unrelated) and transplant number.
Interactions between treatment groups and other predictors
were also investigated. 
The Mantel-Haenszel x2 test was used for statistical
comparisons of the percentage of patient days in emetic
control. For daily scores, a general Wilcoxon test was per-
formed for continuous variables, and a x2 test was used for
categorical endpoints [20]. 
RESULTS
Emetic episodes
We analyzed the number of emetic episodes as least-
square means during the ablative regimen through day 2. In
the entire population, the effect of the administration of
granisetron vs. ondansetron was not significantly different in
the control of emetic episodes. In addition, no significant
differences in efficacy of granisetron or ondansetron on the
control of emesis were observed in the analysis of the pedi-
atric and adult groups individually (Table 2). In multiple
re g ression analysis, no diff e rences were observed between
the drugs based on age, sex, diagnosis (malignancy or no
malignancy), or type of transplant. Patients receiving condi-
tioning regimens including TBI had significantly less emesis
(p 5 0.04) than individuals receiving chemotherapy alone
(Table 3). Data were evaluated only in patients undergoing
their first transplant (the majority of the patients receiving a
Table 2. Nausea and vomiting: effects of ondansetron and granisetron
Mean episodes of emesis/d (95% CI) Mean nausea score/d (95% CI)
Ondansetron Granisetron p Ondansetron Granisetron p
All patients 0.86 (0.67–1.05) 0.73 (0.55–1.91) 0.32 1.29 (1.13–1.45) 1.17 (1.00–1.34) 0.32
Age ,18 y 0.87 (0.63–1.11) 0.54 (0.27–0.81) 0.08 1.14 (0.90–1.38) 0.82 (0.55–1.09) 0.09
Age $18 y 0.86 (0.63–1.09) 0.80 (0.57–1.03) 0.71 1.36 (1.15–1.56) 1.29 (1.09–1.49) 0.65
Table 3. Risk groups for nausea and vomiting
n Mean episodes of emesis/d (95% CI) p Mean nausea score/d (95% CI) p
Sex 0.08 ,0.01
Female 80 0.97 (0.63–1.30) 1.63 (1.34–1.92)
Male 107 0.69 (0.52–0.86) 1.31 (1.06–1.26)
Age 0.71 0.05
,18 y 51 0.82 (0.47–1.17) 1.33 (1.03–1.63)
$18 y 136 0.88 (0.59–1.16) 1.60 (1.36–1.84)
Conditioning 0.04 0.2
Containing TBI 141 0.73 (0.56–0.89) 1.14 (1.00–1.29)
Chemotherapy alone 35 1.06 (0.77–1.34) 1.33 (1.07–1.60)
Multiple regression analysis of emetic episodes and reported nausea in groups undergoing the ablative regimen of bone marrow transplantation. For determinations of
the effects of a conditioning regimen containing either TBI or chemotherapy alone, only patients undergoing their first transplant were considered in the analysis.
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second transplant received a chemotherapy-based re g i m e n ,
which could represent a confounding variable). It should be
recognized that patients undergoing transplantation with
TBI may have diff e rent diagnoses than those underg o i n g
transplants with chemotherapy alone and may have had
v a rying exposures to chemotherapeutic agents before their
transplant experience, which could influence emesis during
their  BMT. We observed that the number of emetic
episodes was relatively constant during the entire pre p a r a-
tive regimen (Fig. 1). However, there appeared to be an
increase in the number of episodes after day 0, primarily in
the pediatric population, when the anti-emetic therapy was
stopped. This phenomenon was less evident in the adult
population. 
Nausea scor e s
In the entire group, we observed no significant diff e r-
ences between the granisetron and ondansetron arms in
nausea experienced by patients. In addition, no significant
d i ff e rences in the re p o rted nausea was observed when the
adult and pediatric populations were evaluated individually
( Table 2). In multivariate analysis comparisons, female
patients experienced more nausea than male patients (p ,
0.01). In addition, less nausea was reported by the pediatric
group in comparison to the adult group (p 5 0.05). No dif-
ferences were apparent in the nausea experienced with con-
ditioning regimens with or without TBI. The severity of
nausea did not appear to increase over time during the
preparative regimens (Fig. 2), but data were not collected on
p e rceived nausea later than day 0, so correlation with the
increased number of emetic episodes could not be assessed. 
D e g r ee of emesis control and administration of
rescue medications
Assessments were made of the number of days of com-
plete, major, and minor control and complete failure for both
d rugs. The data were evaluated as both the pro p o rtion of days
with complete control as well as the number of days with
complete and major control; no diff e rences were observed in
either case (Fig. 3). Information re g a rding the number of
requests for additional anti-emetic medications was analyzed
based on the number of days in which no requests were gen-
erated vs. days when there were any requests for additional
medications, as well as by two or more drugs requested daily
vs. less than two drugs. No diff e rences were observed for the
two drug regimens tested (Fig. 4). 
S a fe t y
Both drugs were well tolerated. In one case (granisetron
arm), the drug was discontinued because of headaches. Simi-
lar numbers of patients in each group re p o rted diffic u l t i e s
with headache (13 patients in each group), diarrh e a
( g r a n i s e t ron, six; ondansetron, two), dizziness (granisetro n ,
four; ondansetron, two), and joint pain (granisetron, five;
ondansetron, one). Less commonly reported effects includ-
ed anxiety, hiccoughs, heart b u rn, and burning/flushing of
the skin. No diff e rences in survival were determined at 30
and 100 days posttransplant. 
DISCUSSION
In this single-institution trial, we compared the capacity
of granisetron and ondansetron to control nausea and vomit-
ing for patients undergoing BMT. Although serotonin antag-
onists have been shown to be well tolerated and more eff e c-
tive than other agents in the conditioning phase of transplan-
tation [9,10,12,13,15], no randomized, blinded comparison
has been perf o rmed in this setting between the two most
commonly used drugs, ondansetron and granisetron. For all
m e a s u res of this important complication of transplantation,
no significant diff e rences were observed between the dru g
regimens tested in the overall transplant population. There
Figure 1. Daily mean emetic episodes
Mean number of emetic episodes experienced by all patients daily during the preparatory regimen associated with transplantation from day –7 to day 2. 
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was a trend toward greater control of both emesis and nausea
in the pediatric patients using granisetron (p 5 0.08 and
0.09) that did not achieve significance. Because granisetron is
less costly in our institution, it is used pre f e rentially in our
BMT patients. Additional savings may be achieved in the use
of oral agents, since there is evidence in patients re c e i v i n g
chemotherapy and in patients undergoing BMT that ade-
quate control may be maintained without the re q u i re m e n t
for intravenous administration [11,21–23]. 
We observed very good overall control of emesis, with
complete control achieved in .60% of patient days for both
d rugs, and major control (one to two episodes of
emesis/day) apparent in an additional 27% of patient days. It
is unclear how much the use of dexamethasone contributed
to this control, since we have not previously tested the effi-
cacy of the serotonin antagonists alone. Others have
o b s e rved a benefit from the inclusion of dexamethasone
with these agents, however [17,24]. Others have re p o rt e d
Figure 2. Daily mean nausea scores
Average nausea score in the entire population of patients as reported daily during the preparatory regimen from day –7 to day 0. 
Figure 3. Control of emesis
Proportion of days in which emesis control is complete, major, minor, or uncontrolled in patients receiving granisetron and ondansetron. Comparison of days achieving
complete control, p 5 0.68; comparison of days achieving complete and major control, p 5 0.68.
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findings similar to ours in patients undergoing BMT,
including a study in which patients were randomized to
receive dexamethasone and 1 mg granisetron once (38%
complete, 41% major control) or twice (45% complete,
43% major control) a day [25]. No data on mean number of
emetic episodes were provided. Gibbs reported a nonblind-
ed but randomized study in which patients undergoing 3–4
days of TBI were randomized to receive oral ondansetron (8
mg twice a day throughout TBI) or a single dose (3 mg) of
intravenous granisetron at the beginning of therapy only. In
that study, the control achieved with ondansetron or
granisetron was comparable in the first 24 hours, but a sin-
gle dose of granisetron was found to be less effective by the
end of therapy [26]. Both of our tested anti-emetic regimens
c o m p a re favorably with observations re p o rted from other
transplant centers. 
We used a continuous infusion of ondansetron in our
study based on our previous experience and re p o rts of eff e c-
tiveness observed by others using an infusion of ondansetro n
at a comparable dose (0.035 µg/kg) [9]. Because the dru g
re q u i res frequent dosing, and because it can be pre p a red as a
single 24-hour infusion, the cost of administering it as a sin-
gle infusion is comparable despite the use of a continuous
infusion pump. Patients generally have a double-lumen right
atrial catheter, and during the preparative regimen one
lumen is dedicated to chemotherapeutic agents and the other
to the ondansetron, thereby avoiding potential incompatibil-
ities. Because granisetron has a longer half-life, little infor-
mation is available re g a rding its use as a continuous infusion;
h o w e v e r, it is possible that it may also prove effective. 
While the majority of studies include only adults, stud-
ies in pediatric populations undergoing BMT have shown
that ondansetron (0.15 mg/kg every 4–6 hours) achieved
rates of complete (41%) and major (30%) responses similar
to those in adults. Patients in this study had a mean of two
episodes of emesis daily [14]. At the Dana Farber Cancer
Center, complete or major control was achieved in 67% of
pediatric patients undergoing transplantation when a load-
ing dose of 0.15 mg/kg ondansetron was administered fol-
lowed by a infusion of 0.019 mg/kg/h [15]. Our results sug-
gesting greater control of emesis may be due to variations in
the dose of ondansetron (continuous infusion of 0.03
mg/kg/h) or the use of dexamethasone [16,27]. While there
is information regarding the use of granisetron in a pediatric
population to prevent nausea associated with chemotherapy
[28,29], we are unaware of other studies reporting its use in
children undergoing transplantation regimens. 
In multiple re g ression analysis, patients receiving a
p reparative regimen other than TBI experienced a signifi-
cantly increased risk of emesis (p 5 0.04). This analysis was
performed only in individuals receiving their first BMT, as
u n d e rgoing a second or third transplant may be associated
with additional toxicity that could be reflected in the degree
of emesis. In addition, patients undergoing a subsequent
transplant are more likely to receive a preparative regimen
consisting of chemotherapy alone and not TBI. Additional-
l y, it should be noted that patients transplanted with TBI-
containing regimens may have had different diagnoses than
those receiving chemotherapy alone, and there f o re may
have had different therapy before transplantation. This dif-
f e rence could also be important in the number of emetic
episodes observed during BMT. The association of TBI-
containing regimens with comparatively less nausea and
vomiting has been observed [14,15]. In our study, however,
t h e re was no significant diff e rence in re p o rted nausea
between conditioning regimens. 
Figure 4. Requests for additional anti-emetic medications
Number of days in each category for patients receiving granisetron and ondansetron. Comparison of days of any additional drugs to none, p . 0.80; comparison
of days of .2 requested drugs to ,2 drugs, p . 0 . 8 0 .
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Evaluation of nausea scores revealed that females had
more reported nausea than males (p , 0.01). Differences in
nausea or vomiting between the sexes has been pre v i o u s l y
described [2,9,23], although we did not observe a significant
d i ff e rence in the number of emetic episodes between
females and males. Evaluation of the effect of age on nausea
and vomiting revealed that children were less likely to
report severe nausea than adults (p 5 0.05). While few prior
studies have made such a comparison, these observ a n c e s
may be in part due to re p o rting diff e rences within the
younger and older pediatric patients, as children in the 5- to
9 - y e a r-old age group re p o rted less nausea (mean nausea
score 1.04; 95% confidence interval [CI] 0.77–1.31) than the
15- to 17-year-old transplant recipients (mean score 1.82;
95% CI 1.20–2.44). 
Our data on the frequency of emesis suggest that there
may be delayed vomiting observed over several days post-
transplant, especially in the pediatric population. Docu-
mentation of delayed nausea and vomiting was not an initial
focus of this study, but in early patients there was a sugges-
tion of delayed emesis and additional information on emesis
was obtained from subsequent patients; however, we did
not collect data on the degree of nausea patients experi-
enced after day 0 and so cannot correlate the vomiting
o b s e rved with nausea scores. It may prove useful to monitor
patients for these delayed effects. Whether sero t o n i n
inhibitors or other agents such as dexamethasone alone are
the optimal therapy for delayed vomiting is unclear
[2,23,30,31]. 
In summary, the use of granisetron or ondansetro n
along with dexamethasone was comparable in the control of
nausea and vomiting associated with the conditioning phase
of transplantation in both children and adults. Both re g i-
mens were well tolerated. There f o re, cost considerations
should be an important determining factor in the choice of
these agents at each institution. 
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